Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Eliquis

- PMLiVE

Bristol Myers Squibb to acquire Mirati Therapeutics for up to $5.8bn

The transaction would mark a significant boost to the US drugmaker’s oncology portfolio

- PMLiVE

Bristol Myers Squibb reveals plans to double number of drugs in registrational trials

The drugmaker expects to expand its research pipeline from six to 12 over next 18 months

- PMLiVE

BMS presents positive six-year results for Opdivo/Yervoy combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

Bristol Myers Squibb’s Camzyos recommended by NICE for inherited heart condition

One in 500 people in the UK are affected by hypertrophic cardiomyopathy

- PMLiVE

BMS pays Zenas $50m upfront for regional rights to autoimmune disease antibody

The company will gain exclusive rights to develop and commercialise obexelimab

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

- PMLiVE

BMS launches campaign to highlight impact of psoriasis on patient well-being

An estimated 7.5 million people in the US are affected by some form of the condition

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by CHMP for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

- PMLiVE

BMS obtains global rights to Prothena’s Alzheimer’s drug in deal worth $2.2bn

The decision comes two years after the company paid $80m for opt-in rights to PRX005

- PMLiVE

Bristol Myers Squibb’s Sotyktu recommended by NICE for plaque psoriasis

An estimated 1.8 million people in the UK are affected by some form of the condition

- PMLiVE

BMS presents positive four-year results for Opdivo combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

BMS and Janssen’s antithrombotic granted FDA fast track designation

The three indications include ischaemic stroke, acute coronary syndrome and atrial fibrillation

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links